BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mongan D, Sabherwal S, Susai SR, Föcking M, Cannon M, Cotter DR. Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies. Schizophr Res 2020;222:58-72. [PMID: 32456884 DOI: 10.1016/j.schres.2020.05.036] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Mohd Asyraf AJ, Nour El Huda AR, Hanisah MN, Noorul Amilin H, Norlelawati AT. DNA methylation and copy number variation of the complement C4A gene in schizophrenia. Gene Reports 2022;29:101702. [DOI: 10.1016/j.genrep.2022.101702] [Reference Citation Analysis]
2 Susai SR, Healy C, Mongan D, Heurich M, Byrne JF, Cannon M, Cagney G, Wynne K, Markulev C, Schäfer MR, Berger M, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EYH, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Street R, Thompson A, Yung AR, Nelson B, McGorry PD, Föcking M, Amminger GP, Cotter D. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Transl Psychiatry 2022;12:454. [PMID: 36307392 DOI: 10.1038/s41398-022-02217-0] [Reference Citation Analysis]
3 Chen S, Gou M, Chen W, Xiu M, Fan H, Tan Y, Tian L. Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls. Front Psychiatry 2022;13:1024299. [DOI: 10.3389/fpsyt.2022.1024299] [Reference Citation Analysis]
4 Chen Q, Sun T, Li D, Zhao Z, Li Y. The differences in serum C1q levels between first-episode patients with bipolar disorder and major depressive disorder. J Psychosom Res 2022;162:111042. [PMID: 36156342 DOI: 10.1016/j.jpsychores.2022.111042] [Reference Citation Analysis]
5 Liu C, Liu C, Hsieh M, Hwang T, Lin Y, Chien Y, Hwu H. The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis. Psychiatry Research 2022. [DOI: 10.1016/j.psychres.2022.114775] [Reference Citation Analysis]
6 Susai SR, Mongan D, Healy C, Cannon M, Cagney G, Wynne K, Byrne JF, Markulev C, Schäfer MR, Berger M, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EYH, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Street R, Thompson A, Ruth Yung A, Nelson B, McGorry PD, Föcking M, Paul Amminger G, Cotter D. Machine learning based prediction and the influence of complement - Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. Brain Behav Immun 2022;103:50-60. [PMID: 35341915 DOI: 10.1016/j.bbi.2022.03.013] [Reference Citation Analysis]
7 Waszczuk K, Kucharska-mazur J, Tyburski E, Rek-owodziń K, Plichta P, Rudkowski K, Podwalski P, Grąźlewski T, Mak M, Misiak B, Michalczyk A, Tarnowski M, Sielatycka K, Szczęśniak A, Łuczkowska K, Dołęgowska B, Budkowska M, Ratajczak MZ, Samochowiec J. Psychopathology and Stem Cell Mobilization in Ultra-High Risk of Psychosis and First-Episode Psychosis Patients. IJERPH 2022;19:6001. [DOI: 10.3390/ijerph19106001] [Reference Citation Analysis]
8 Ermakov EA, Melamud MM, Buneva VN, Ivanova SA. Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives. Front Psychiatry 2022;13:880568. [PMID: 35546942 DOI: 10.3389/fpsyt.2022.880568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Hatzimanolis A, Foteli S, Stefanatou P, Ntigrintaki AA, Ralli I, Kollias K, Nikolaou C, Gazouli M, Stefanis NC. Deregulation of complement components C4A and CSMD1 peripheral expression in first-episode psychosis and links to cognitive ability. Eur Arch Psychiatry Clin Neurosci 2022. [PMID: 35532796 DOI: 10.1007/s00406-022-01409-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Suhas S, Mehta UM. A redux of schizophrenia research in 2021. Schizophr Res 2022:S0920-9964(22)00130-X. [PMID: 35300898 DOI: 10.1016/j.schres.2022.03.003] [Reference Citation Analysis]
11 Thylur DS, Goldsmith DR. Brick by Brick: Building a Transdiagnostic Understanding of Inflammation in Psychiatry. Harv Rev Psychiatry 2022;30:40-53. [PMID: 34995034 DOI: 10.1097/HRP.0000000000000326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Mohd Asyraf AJ, Nour El Huda AR, Hanisah MN, Norsidah KZ, Norlelawati AT. Relationship of selective complement markers with schizophrenia. J Neuroimmunol 2021;363:577793. [PMID: 34990981 DOI: 10.1016/j.jneuroim.2021.577793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Jiang J, He S, Liu K, Yu K, Long P, Xiao Y, Liu Y, Yu Y, Wang H, Zhou L, Zhang X, He M, Guo H, Wu T, Yuan Y. Multiple plasma metals, genetic risk and serum complement C3, C4: A gene-metal interaction study. Chemosphere 2021;:132801. [PMID: 34752839 DOI: 10.1016/j.chemosphere.2021.132801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Da Silva T, Guma E, Hafizi S, Koppel A, Rusjan P, Kennedy JL, Chakravarty MM, Mizrahi R. Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology. Biol Psychiatry 2021;90:652-60. [PMID: 34456009 DOI: 10.1016/j.biopsych.2021.06.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Susai SR, Mongan D, Healy C, Cannon M, Nelson B, Markulev C, Schäfer MR, Berger M, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EYH, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung AR, McGorry PD, Föcking M, Cotter D, Amminger GP. The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. Brain Behav Immun 2021;99:147-56. [PMID: 34624483 DOI: 10.1016/j.bbi.2021.09.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Kalinowski A, Liliental J, Anker LA, Linkovski O, Culbertson C, Hall JN, Pattni R, Sabatti C, Noordsy D, Hallmayer JF, Mellins ED, Ballon JS, O'Hara R, Levinson DF, Urban AE. Increased activation product of complement 4 protein in plasma of individuals with schizophrenia. Transl Psychiatry 2021;11:486. [PMID: 34552056 DOI: 10.1038/s41398-021-01583-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Gracia DFK, Gomes EMP, Coelho TA, Carriello M, de Andrade FA, Bavia L, Messias-Reason IJ, Massuda R. Ficolin activation as a potential biomarker of the severity of schizophrenia. Psychiatry Res 2021;304:114122. [PMID: 34303139 DOI: 10.1016/j.psychres.2021.114122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Izuo N, Nitta A. New Insights Regarding Diagnosis and Medication for Schizophrenia Based on Neuronal Synapse-Microglia Interaction. J Pers Med 2021;11:371. [PMID: 34063598 DOI: 10.3390/jpm11050371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Germann M, Brederoo SG, Sommer IEC. Abnormal synaptic pruning during adolescence underlying the development of psychotic disorders. Curr Opin Psychiatry 2021;34:222-7. [PMID: 33560023 DOI: 10.1097/YCO.0000000000000696] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
20 Cathomas F, Klaus F, Guetter K, Chung HK, Raja Beharelle A, Spiller TR, Schlegel R, Seifritz E, Hartmann-Riemer MN, Tobler PN, Kaiser S. Increased random exploration in schizophrenia is associated with inflammation. NPJ Schizophr 2021;7:6. [PMID: 33536449 DOI: 10.1038/s41537-020-00133-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]